Generated by AI
Neurogene Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for rare neurological diseases. Its current pipeline centers on gene therapy programs designed to address severe disorders such as Rett syndrome and CLN5 Batten disease, with candidates that use adeno-associated virus delivery and proprietary transgene regulation technology to control gene expression in the central nervous system. Neurogene’s work is aimed at treating conditions with significant unmet medical need, where conventional approaches have limited impact on the underlying cause of disease. The company also operates gene therapy manufacturing capabilities to support clinical development and production of its programs. Headquartered in New York, Neurogene Inc. is part of the broader biotechnology and rare-disease therapeutics market, where it contributes to the advancement of precision genetic medicine for devastating neurological disorders.
Website535 W 24th Street
New York, NY, 10011
United States
The latest articles about NGNE.
NEW YORK, November 05, 2026--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 2,010 shares of the Company’s common stock to one new employee (the "Inducement Grant") on November 3, 2026 (the "Grant Date"). The Inducem
Summary of Feb 27's posts. Generated by AI.
No summary yet.
Summary of Feb 27's posts. Generated by AI.
No summary yet.
Summary of Feb 27's posts. Generated by AI.
Investors talking about NGNE also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.